Unveiling causal immune cell–gene associations in multiple myeloma: insights from systematic reviews and Mendelian randomization analyses
Our study supports the efficacy and safety of CAR-T-cell therapy in rrMM patients, with an 82.2% ORR and low rates of severe CRS (6.3%) and neurotoxicity (0.9%). This finding also suggests that BCMA/CD19 bispecific CAR-T cells have a superior ORR, pending clinical confirmation. MR analysis reveals links between immune cells, genes such as VDR and VHL, and MM, enhancing our understanding of its pathophysiology.
Authors
- Jing-Xuan Lian
- Zheng Jin-gui (ORCID: https://orcid.org/0000-0003-4976-9024)
- Litian Ma (ORCID: https://orcid.org/0000-0002-7177-4439)
- Can-Jun Zhao (ORCID: https://orcid.org/0000-0002-4268-3204)
- Yu Zhu (ORCID: https://orcid.org/0000-0002-3332-5202)
- Hui Zhang (ORCID: https://orcid.org/0000-0002-4283-7971)
- Ling Zhang (ORCID: https://orcid.org/0009-0002-0889-7580)
- Zengqiang Kou (ORCID: https://orcid.org/0009-0006-2879-5855)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Dongguan University of Technology (CN)
- Integrated Chinese Medicine (China) (HK)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3389/fmed.2025.1456732
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00